Shamkant Mulgaonkar - Concepedia

Author

Shamkant Mulgaonkar

Saint Barnabas Medical Center

Also Known As

Shamkant Mulgaonkar, Shamkant P. Mulgaonkar

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

Saint Barnabas Medical Center Hospital do Rim e Hipertensão University of California, San Francisco Novartis (Switzerland)Medical University of South Carolina

About

Shamkant Mulgaonkar is an author at Saint Barnabas Medical Center specializing in kidney transplant, medicine, and nephrology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	360
2	Nephrology	6	6	303
3	Immunology	2	2	211
4	Pharmacology	2	2	39
5	Transplantation Surgery	2	2	63

Shamkant Mulgaonkar

Publications

2.6K

Citations

H-Index

Page 1

	Year	Citations
Alemtuzumab Induction in Renal Transplantation Michael J. Hanaway, E. Steve Woodle, Shamkant Mulgaonkar, New England Journal of Medicine	2011	374
Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation Julio Pascual, Stefan P. Berger, Oliver Witzke, Journal of the American Society of Nephrology	2018	239
Everolimus versus Mycophenolate Mofetil in the Prevention of Rejection in De Novo Renal Transplant Recipients: A 3-Year Randomized, Multicenter, Phase III Study Marc I. Lorber, Shamkant Mulgaonkar, Khalid M.H. Butt, Transplantation	2005	231
FTY720, A Novel Immunomodulator: Efficacy and Safety Results from the First Phase 2A Study in de novo Renal Transplantation Hélio Tedesco‐Silva, Georges Mourad, Barry D. Kahan, Transplantation	2004	216
Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial Matthew R. Weir, Shamkant Mulgaonkar, Laurence Chan, Kidney International UrologyTransplantationKidney TransplantKidney TransplantationSolid Organ Transplantation	2010	183
Patient-Reported Gastrointestinal Symptom Burden and Health-Related Quality of Life following Conversion from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium Laurence Chan, Shamkant Mulgaonkar, Rowan G. Walker, Transplantation	2006	158
Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study Stefan P. Berger, Claudia Sommerer, Oliver Witzke, American Journal of Transplantation	2019	145
Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study Barry D. Kahan, Janet L. Karlix, Ronald M. Ferguson, Transplantation	2003	126
HYPERCOAGULABLE STATES IN RENAL TRANSPLANT CANDIDATES: IMPACT OF ANTICOAGULATION UPON INCIDENCE OF RENAL ALLOGRAFT THROMBOSIS Gary S. Friedman, Herwig‐Ulf Meier‐Kriesche, Bruce Kaplan, Transplantation	2001	112
Randomized Controlled Trial of FTY720 Versus MMF in De Novo Renal Transplantation Hélio Tedesco‐Silva, Mark D. Pescovitz, Diane M. Cibrik, Transplantation	2006	107

Page 1